KalVista Pharmaceuticals (KALV) Price & Analysis

Compare

520 Followers

KALV Stock Chart & Stats

Day’s Range― - ―

52-Week Range$7.30 - $16.32

Previous CloseN/A

Volume49.40K

Average Volume (3M)901.72K

Market Cap

$648.90M

Enterprise Value$576.80M

Total Cash (Recent Filing)$187.65M

Total Debt (Recent Filing)$6.31M

Price to Earnings (P/E)―

Beta1.12

Next Earnings

Sep 04, 2025

EPS Estimate

-0.96

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.99

Shares Outstanding49,953,740

10 Day Avg. Volume651,052

30 Day Avg. Volume901,718

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.89

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit2.57K

Enterprise Value/Ebitda-3.33

Forecast

1Y Price Target

$31.67

Price Target Upside140.65% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe company has a strong cash balance to support the launch of Ekterly, providing financial stability for future operations.

Market PositionKalVista grants Kaken Pharmaceutical Japanese commercial rights to sebetralstat ahead of a likely approval, which could enhance the company's market position.

Market PotentialSebetralstat is poised to be the first on-demand HAE drug for approximately 2,500 Japanese patients, indicating a strong market potential.

Bears Say

Formulary LimitationsOne KOL was skeptical that Ekterly would ever be broadly added to formularies, suggesting it may only be available through medical exception pathways—a process that could place a substantial documentation burden on physician practices.

Reimbursement ChallengesConsensus optimism is tempered by a key caveat: as KOLs emphasized that the 50% switch rate would only be realistic if the drug is reimbursed.

KalVista Pharmaceuticals News

KalVista confirms maintenance of orphan designation for sebetralstat

KalVista (KALV) announced that the Committee for Orphan Medicinal Products of the European Medicines Agency confirmed maintenance of...

16d ago

KALV

KalVista Pharmaceuticals Updates Stockholder Meeting Schedule

KalVista Pharmaceuticals ( ($KALV) ) just unveiled an announcement. KalVista Pharmaceuticals has announced that its 2026 Annual Meeting...

6d ago

KALV

KalVista receives CHMP opinion recommending sebetralstat marketing authorization

KalVista (KALV) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has...

1M ago

KALV

Buy Rating for KalVista Pharmaceuticals: Strong Growth Potential Following Ekterly’s FDA Approval and Strategic Financial Positioning

Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on KalVista Pharmaceuticals and increased the price target to...

1M ago

KALV

KalVista announces MHRA approval of Ekterly

KalVista (KALV) Pharmaceuticals announced that the Medicines and Healthcare products Regulatory Agency of the United Kingdom has granted...

1M ago

KALV

KalVista Pharmaceuticals: EKTERLY Launch and Financial Update

KalVista Pharmaceuticals, Inc. ( ($KALV) ) has released its Q4 earnings. Here is a breakdown of the information...

2M ago

KALV

KalVista Pharmaceuticals: Buy Rating Affirmed Amidst Promising Ekterly Launch and Strong Financial Position

KalVista Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from...

2M ago

KALV

Buy Rating for KalVista Pharmaceuticals Amid Ekterly’s Market Launch and Insurance Challenges

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on KalVista Pharmaceuticals today and set a price target...

2M ago

KALV

KalVista price target lowered to $27 from $30 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on KalVista (KALV) to $27 from $30 and keeps a Buy...

2M ago

KALV

KalVista price target raised to $37 from $22 at BofA

BofA raised the firm’s price target on KalVista (KALV) to $37 from $22 and keeps a Buy rating...

2M ago

KALV

KalVista price target raised to $27 from $19 at Citizens JMP

Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on KalVista (KALV) to $27 from $19 and...

2M ago

KALV

KalVista price target raised to $20 from $18 at Leerink

Leerink analyst Joseph P. Schwartz raised the firm’s price target on KalVista (KALV) to $20 from $18 and...

2M ago

KALV

Buy Rating for KalVista Pharmaceuticals Driven by FDA Approval and Strategic Market Entry of Ekterly

JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on KalVista Pharmaceuticals today and set a price target of...

2M ago

KALV

KalVista price target raised to $40 from $32 at Jefferies

Jefferies analyst Maury Raycroft raised the firm’s price target on KalVista (KALV) to $40 from $32 and keeps...

2M ago

KALV

KALV FAQ

What was KalVista Pharmaceuticals’s price range in the past 12 months?

KalVista Pharmaceuticals lowest stock price was $7.30 and its highest was $16.32 in the past 12 months.

What is KalVista Pharmaceuticals’s market cap?

KalVista Pharmaceuticals’s market cap is $648.90M.

When is KalVista Pharmaceuticals’s upcoming earnings report date?

KalVista Pharmaceuticals’s upcoming earnings report date is Sep 04, 2025 which is in 8 days.

How were KalVista Pharmaceuticals’s earnings last quarter?

KalVista Pharmaceuticals released its earnings results on Jul 10, 2025. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.799 by -$0.191.

Is KalVista Pharmaceuticals overvalued?

According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does KalVista Pharmaceuticals pay dividends?

KalVista Pharmaceuticals does not currently pay dividends.

What is KalVista Pharmaceuticals’s EPS estimate?

KalVista Pharmaceuticals’s EPS estimate is -0.96.

How many shares outstanding does KalVista Pharmaceuticals have?

KalVista Pharmaceuticals has 49,953,740 shares outstanding.

What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?

KalVista Pharmaceuticals reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.799. Following the earnings report the stock price went down -3.002%.

Which hedge fund is a major shareholder of KalVista Pharmaceuticals?

Currently, no hedge funds are holding shares in KALV

KalVista Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-121.50%

Trailing 12-Months

Asset Growth

6.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

KalVista Pharmaceuticals

KalVista Pharmaceuticals (KALV) is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet needs. Operating primarily in the biotechnology sector, KalVista is dedicated to developing treatments for hereditary angioedema (HAE) and other plasma kallikrein-related diseases. The company's lead product candidate, sebetralstat, is being developed as a potential oral on-demand treatment for HAE attacks.

KalVista Pharmaceuticals (KALV) Earnings & Revenues

Historic Earnings Reports

KALV Stock 12 Month Forecast

Average Price Target

$31.67

▲(140.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","24":"$24","41":"$41","15.5":"$15.5","32.5":"$32.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,15.5,24,32.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.59,13.775384615384615,15.96076923076923,18.146153846153844,20.33153846153846,22.516923076923078,24.70230769230769,26.887692307692305,29.073076923076922,31.258461538461535,33.44384615384615,35.62923076923077,37.81461538461538,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.59,13.134615384615385,14.67923076923077,16.223846153846154,17.768461538461537,19.313076923076924,20.857692307692307,22.402307692307694,23.946923076923078,25.49153846153846,27.036153846153848,28.58076923076923,30.125384615384615,{"y":31.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.59,12.236923076923077,12.883846153846154,13.53076923076923,14.177692307692308,14.824615384615385,15.471538461538461,16.11846153846154,16.765384615384615,17.412307692307692,18.05923076923077,18.706153846153846,19.353076923076923,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.18,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.67,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.89,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.39,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.39,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.61,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.47,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.91,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >